Pirfenidone is an inhibitor for TGF-β production and TGF-β stimulated collagen production, reduces production of TNF-α and IL-1β, and also has anti-fibrotic and anti-inflammatory properties. Pirfenidone attenuates chemokine (CC motif) ligand-2 (CCL2) and CCL12 production with anti-fibrotic activity. Phase 3.
More Information Supplier PageTempol (4-Hydroxy-TEMPO) is a superoxide scavenger that displays neuroprotective, anti-inflammatory and analgesic effects. Phase 2.
More Information Supplier PageGo 6983 (GOE 6983, Gö 6983) is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ and PKCδ with IC50 of 7 nM, 7 nM, 6 nM and 10 nM, respectively; less potent to PKCζ and inactive to PKCμ.
More Information Supplier PageWZ811 is a highly potent competitive CXCR4 antagonist with EC50 of 0.3 nM.
More Information Supplier PageWZ811 is a highly potent competitive CXCR4 antagonist with EC50 of 0.3 nM.
More Information Supplier PageBAY 11-7082 (BAY 11-7821) is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21 with IC50 of 0.19 μM and 0.96 μM, respectively. BAY 11-7082 induces apoptosis and S phase arrest in gastric cancer cells.
More Information Supplier PageCobicistat is a potent and selective inhibitor of CYP3A with IC50 of 30-285 nM.
More Information Supplier PageCCG 50014 is a potent and selective inhibitor of RGS4 with IC50 of 30 nM.
More Information Supplier PageS-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. Phase 3.
More Information Supplier Page
